|
|||||
|
|
| 转移性激素敏感性前列腺癌研究进展 | |
| 引用本文： | 刘 鑫,张劲松,王海峰. 转移性激素敏感性前列腺癌研究进展[J]. 医学信息, 2019, 0(15): 30-33. DOI: 10.3969/j.issn.1006-1959.2019.15.011 |
| 作者姓名： | 刘 鑫 张劲松 王海峰 |
| 作者单位： | 昆明医科大学第二附属医院泌尿外科一病区，云南 昆明 650032 |
| 摘 要： | 在过去的七十多年，转移性激素敏感性前列腺癌（mHSPC）的标准治疗一直都是单独使用雄激素剥夺治疗（ADT）。直到近几年研究显示，多西他赛（DOC）联合ADT可显著提高mHSPC患者的生存率，引起了mHSPC治疗标准的改变。近期研究证实，ADT结合醋酸阿比特龙（AA）和泼尼松（P）同样可以改善mHSPC的生存率。因此，本文将结合近期临床试验，综述mHSPC治疗的新进展。 |
| 关 键 词： | 转移性激素敏感性前列腺癌 雄激素剥夺治疗 多西他赛 醋酸阿比特龙 |
Research Progress on the Metastatic Hormone-sensitive Prostate Cancer |
|
| LIU Xin,ZHANG Jin-song,WANG Hai-feng. Research Progress on the Metastatic Hormone-sensitive Prostate Cancer[J]. Medical Information, 2019, 0(15): 30-33. DOI: 10.3969/j.issn.1006-1959.2019.15.011 | |
| Authors: | LIU Xin ZHANG Jin-song WANG Hai-feng |
| Affiliation: | Department of Urology,Ward One,the Second Affiliated Hospital of Kunming Medical University, Kunming 650032,Yunnan,China |
| Abstract: | Abstract:For the past seventy years, standard treatment for metastatic sex hormone-sensitive prostate cancer (mHSPC) has been the use of androgen deprivation therapy (ADT) alone. Until recent studies have shown that docetaxel (DOC) combined with ADT can significantly improve the survival rate of mHSPC patients, leading to changes in the treatment criteria of mHSPC. Recent studies have confirmed that ADT combined with Abiraterone Acetate (AA) and prednisone (P) can also improve the survival rate of mHSPC. Therefore, this article will combine the results of recent clinical trials to review the latest advances in mHSPC therapy. |
| Keywords: | Key words:Metastatic hormone-sensitive prostate cancer Androgen deprivation therapy Docetaxel Abiraterone acetate |
| 点击此处可从《医学信息》浏览原始摘要信息 | |
| 点击此处可从《医学信息》下载免费的PDF全文 | |